Results 101 to 110 of about 24,853 (244)

Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia

British Journal of Haematology
Large granular lymphocytic (LGL) leukaemia is a rare chronic lymphoproliferative disorder characterized by an expansion of cytotoxic T or NK cells.
Tony Marchand, Cédric Pastoret, Gandhi Damaj, Angélique Lebouvier, C. Herbaux, A. Moignet, Miguel Pavlosky, Astrid Pavlosky, Anaïse Blouet, Martin Eloit, V. Launay, P. Lebreton, A. Stamatoullas, Christer Nilsson, M. Ochmann, Juliette Prola, Thierry Lamy   +16 more
semanticscholar   +1 more source

Emerging Paediatric Uses of Dupilumab Beyond Approvals

Clinical &Experimental Allergy, EarlyView.
Dupilumab, through IL‐4Rα blockade, shows promising efficacy beyond approved indications in paediatric diseases driven by T2 inflammation. Emerging evidence—mainly from small studies—supports improvements in disease severity and quality of life, highlighting its potential as a targeted, steroid‐sparing therapy while underscoring the need for ...
Simone Foti Randazzese, Anna Calamita, Diletta D'Angelo, Alessia Marseglia, Esther Mesa Lombardero, Sara Pedersoli, Micol Tedeschi, Mara De Amici, Sara Manti, Valeria Brazzelli, Amelia Licari, Gian Luigi Marseglia   +11 more
wiley   +1 more source

A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease

Journal of Clinical Oncology
PURPOSE Sclerotic chronic graft-versus-host disease (cGVHD) represents a highly morbid and refractory form of cGVHD, and novel therapies for sclerotic cGVHD are critically needed. This study aimed to determine the efficacy of ruxolitinib in patients with
V. Bhatt, Valerie K. Shostrom, Hannah Choe, Betty K. Hamilton, Krishna Gundabolu, Lori J. Maness, Virender Kumar, Ram I. Mahato, Lynette M. Smith, T. Nishihori, Stephanie J. Lee   +10 more
semanticscholar   +1 more source

Squamoid Eccrine Ductal Carcinoma: Case Series of a Rare, Potentially Aggressive Skin Cancer Associated With Immunosuppression

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Squamoid Eccrine Ductal Carcinoma (SEDC) is a rare cutaneous adenexal carcinoma first described in 1997. It has distinct biphasic features on histology which commonly result in misdiagnosis as Bowen disease or cutaneous squamous cell carcinomas (cSCC) if diagnostic skin biopsies are too superficial. This may lead to a delay in diagnosis. It is
Xiang Li Tan, Pooja Patel, Jeva Cernova, Sarah Hogan, Jason Thomson, Efthymios Hadjimichael, Sharanpal Jeetle, Dorota Markiewicz, Michael Sheaff, Nilukshi Wijesuriya, Mark Hawthorne, Graeme Moir, Matthew Stodell, Kapil Bhargava, Suchitra Chinthapalli, Catherine A. Harwood   +15 more
wiley   +1 more source

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study

Annals of Hematology
Ruxolitinib is beneficial in patients with myelofibrosis (MF) and polycythemia vera (PV). Information on ruxolitinib adherence is scant. The Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera (RAMP) prospective multicenter study (NCT06078319 ...
F. Palandri, G. Auteri, E. Abruzzese, G. Caocci, M. Bonifacio, F. Mendicino, R. Latagliata, A. Iurlo, F. Branzanti, B. Garibaldi, M. Trawinska, D. Cattaneo, M. Krampera, O. Mulas, E. Martino, M. Cavo, N. Vianelli, S. Impera, F. Efficace, F. Heidel, M. Breccia, E. Elli, G. Palumbo   +22 more
semanticscholar   +1 more source

Elevated IL‐4 and IL‐13 Expression in Hailey‐Hailey Disease: Evidence for Th2‐Mediated Pathogenesis and Targeted Treatment

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Hailey‐Hailey disease (HHD) is a rare autosomal dominant blistering disorder caused by mutations in the ATP2C1 gene, which impair keratinocyte adhesion through disrupted calcium signaling. While traditionally considered a structural defect, recent studies suggest that Th2‐mediated inflammation may exacerbate disease pathology ...
Simonetta I. Gaumond, Victoria Soto, Beatriz Abdo Abujamra, Franco Rongioletti, John A. McGrath, Ivan Jozic, Paolo Romanelli   +6 more
wiley   +1 more source

Clinical considerations for ruxolitinib in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) and steroid-refractory or -dependent chronic GVHD: a plain language summary

Therapeutic Advances in Hematology
Summary What is this summary about? Ruxolitinib (JAKAFI ® ) is a Janus kinase (JAK) 1 and JAK2 inhibitor that is approved for acute and chronic graft-versus-host disease (GVHD).
Zahra Mahmoudjafari, Valkal Bhatt, Zhenyi Xue, Franco Locatelli, Gérard Socié, Robert Zeiser   +5 more
doaj   +1 more source

Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies

Journal of Dermatological Treatment
Purpose: Ruxolitinib (selective Janus kinase [JAK] 1 and JAK2 inhibitor) cream demonstrated efficacy and safety in patients with atopic dermatitis (AD) in the phase 3 TRuE-AD studies. In TRuE-AD1/TRuE-AD2 (NCT03745638/NCT03745651), adults and adolescents
Eric L. Simpson, Robert Bissonnette, Zelma C. Chiesa Fuxench, Howard Kallender, Daniel Sturm, Haobo Ren, Linda F. Stein Gold   +6 more
doaj   +1 more source

Ruxolitinib Phosphate

American Journal of Health-System Pharmacy, 2021
openaire   +2 more sources

Out‐of‐pocket costs and time spent on disease management by vitiligo patients: a cross‐sectional questionnaire study in German‐speaking countries

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives The financial and time‐related burden of patients with vitiligo remains insufficiently studied. This study aimed to quantify out‐of‐pocket costs (OOPC) and time expenditure for vitiligo management and the associated sociodemographic, clinical, and behavioral factors in German‐speaking countries.
Christine Gasteiger, Michael Hindelang, Stefanie Ziehfreund, Hannah Wecker, Tilo Biedermann, Alexander Zink   +5 more
wiley   +1 more source